Celcuity (CELC) Gains from Investment Securities (2017 - 2025)
Celcuity (CELC) reported Gains from Investment Securities of $23.6 million for Q4 2025, up 38241.94% on a YoY basis from N/an in Q4 2024, and up 98.37% quarter-over-quarter from $11.9 million in Q3 2025.
Celcuity (CELC) Gains from Investment Securities (2017 - 2025) Analysis & Trends
Celcuity has reported Gains from Investment Securities for 9 years, with the latest figure at $23.6 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 38241.94% year-over-year to $23.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.7 million (up 23638.25% YoY), and the FY2025 full-year result was $34039.0, down 99.21% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $23.6 million, up from $11.9 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $23.6 million in Q4 2025, with the low at -$62000.0 in Q4 2024.
- Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $402550.0 in 2021.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities sank 99.89% — and 2023, when it surged 141769.55%.
- Celcuity's Gains from Investment Securities stood at $1.3 million in 2021, then slumped by 99.89% to $1466.0 in 2022, then soared by 4388.2% to $65797.0 in 2023, then plunged by 194.23% to -$62000.0 in 2024, then soared by 38241.94% to $23.6 million in 2025.
- The last three Gains from Investment Securities figures came in at $23.6 million (Q4 2025), $11.9 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.65 Mn |
| Dec 31, 2025 | 23.65 Mn |
| Sep 30, 2025 | 11.92 Mn |
| Sep 30, 2025 | 11.92 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | -62,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 552,179.00 |
| Jun 30, 2024 | 552,179.00 |
| Mar 31, 2024 | 15,250.00 |
| Mar 31, 2024 | 15,250.00 |
| Sep 30, 2023 | 65,797.00 |
| Sep 30, 2023 | 65,797.00 |
| Jun 30, 2023 | 310,798.00 |
| Jun 30, 2023 | 310,798.00 |